Personalized Neoadjuvant Chemotherapy for Gastrointestinal Cancers: Shaping Imprecision to be Precise

Area of Science:

• Oncology
• Gastrointestinal Cancer Research
• Precision Medicine

Background:

• Neoadjuvant chemotherapy offers potential benefits like tumor reduction and decreased recurrence in gastrointestinal cancers.
• Current treatment protocols are often generalized, lacking personalization and leading to suboptimal outcomes for many patients.
• Tumor heterogeneity and varying responses to standard regimens highlight the need for more precise therapeutic approaches.

Purpose of the Study:

• To emphasize the critical role of harnessing tumor biology for developing predictive signatures in personalized neoadjuvant chemotherapy.
• To explore how individualized treatment strategies can improve surgical candidacy and reduce treatment intensity for gastrointestinal malignancies.
• To advocate for the integration of precision approaches to enhance neoadjuvant chemotherapy efficacy and patient outcomes.

Main Methods:

• Utilizing transcriptomics to analyze patient biopsies and understand molecular underpinnings of treatment response.
• Identifying existing and novel therapeutic agents based on identified tumor vulnerabilities and preclinical data.
• Comparing outcomes of molecularly distinct patient groups receiving tailored versus standard chemotherapy regimens.

Main Results:

• Evidence suggests actionable sensitivities and targetable dependencies exist in most gastrointestinal tumors, supporting personalized treatment.
• Individualized neoadjuvant chemotherapy holds promise for increasing curative surgery rates in treatment-resistant cancers like biliary tract and pancreatic ductal adenocarcinoma.
• Tailored chemotherapy may allow for dose de-escalation and reduced morbidity in more sensitive cancers without compromising oncological results.

Conclusions:

• Personalized neoadjuvant chemotherapy, guided by tumor biology, is essential for optimizing treatment for gastrointestinal cancers.
• Developing predictive signatures is crucial for matching patients to the most effective chemotherapy regimens or novel agents.
• Implementing precision approaches can significantly improve neoadjuvant treatment outcomes, reduce toxicity, and increase the potential for curative surgery.